GERON CORP
GERNNASDAQ🏆 #2733 by market capEarnings Nov 4US Equity
$0.97▼ $0.18 (−15.55%)
After hours · at closeTrack GERN
Get earnings, price moves & breaking news on Telegram
24h▼ 15.6%
7d▼ 15.6%
14d▼ 18.7%
30d▼ 22.3%
ytd▼ 27.0%
1y▼ 24.5%
🏦Market Cap
$621M
Small Cap
📈Revenue Growth (YoY)
24.4%
Healthy
📊Gross Margin
96.6%
High
💵FCF Margin
13.9%
Healthy
⚖️P/S Ratio
3.7x
Fair
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $0.84 – $1.04
- 52-Week Range
- $1.04 – $2.01
- Volume (shares)
- 2,958,826
- Avg Volume (shares)
- —
- Shares Outstanding
- 642.5M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 3.7x
- EPS (TTM)
- $-0.10
- Dividend Yield
- —
GERON CORP
GERNFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout GERON CORP
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
11 analysts
Strong Buy4
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.